Acquisition Press Release Examples [+ Templates]

Amplix Expands Portfolio with Acquisition of Florida-Based Trusted Advisor nQuery Communications

NORWOOD, Mass., Oct. 30, 2023 /PRNewswire/ — Amplix, a portfolio company of Gemspring Capital and a leading provider of technology advisory services and software, today announced the acquisition of substantially all of the assets of M.J.M. ENTERPRISES, LLC., dba nQuery Communications (“nQuery”). Terms of the transaction were not disclosed.

Founded in 2003 and based in Miami, Florida, nQuery serves as a trusted advisor to approximately 250 enterprise and SMB customers across various end markets. nQuery provides best-in-class, unbiased advisory services across a range of cloud-oriented offerings – including unified communications, business internet, contact center, and IT and cybersecurity – to help customers evaluate and implement the most efficient and reliable services across their businesses. Over the past 20 years, nQuery has developed a diversified base of customers in the rapidly expanding Florida market, distinguished by its reputation for providing exceptional, hands-on service.

Joe DeStefano, the CEO of Amplix, commented, “nQuery’s integration into the Amplix platform is a significant strategic milestone for our business. nQuery will bolster our existing presence in the flourishing Florida region, ultimately benefiting both our existing and new clients. We eagerly anticipate collaborating with the talented team at nQuery to further enhance the technology investment returns for our combined base of valued customers.”

Emilio Diaz, the Founder of nQuery, shared, “Our partnership with Amplix marks an exciting chapter in nQuery’s journey of growth and innovation, and aligns seamlessly with our commitment to delivering exceptional value to our customers. We are thrilled to complement our service offerings with the additional resources, capabilities and scale of the Amplix platform.”

About nQuery

nQuery is a provider of technology advisory services and software to customers across multiple industries, serving as a trusted resource to its clients by enabling IT professionals to make more informed decisions to optimize technology spending. nQuery’s advisory services span connectivity, cloud telephony, and managed services. nQuery is headquartered in Miami, Florida. For more information, visit www.nquerysolutions.com.

About Amplix

Amplix is a provider of strategic technology advisory, consulting, implementation, and managed services to more than 3,500 customers nationwide, enabling data-driven enhancements to technology decision-making and optimization. Amplix advisory services encompass customer experience, data connectivity, security, and managed services, cloud telephony, mobility, cloud optimization, business continuity, and data center solutions. Amplix is headquartered in Norwood, Massachusetts with over 150 employees in over 20 states and Canada. For more information, visit www.amplix.com.

About Gemspring Capital

Gemspring Capital, a Westport, Connecticut-based private equity firm with $3.5 billion of capital under management, provides flexible capital solutions to middle market companies. Gemspring partners with talented management teams and takes a partnership approach to helping drive revenue growth, value creation and sustainable competitive advantages. Target companies have up to $500 million in revenue and are in the aerospace & defense, business services, consumer services, financial and insurance services, healthcare services, industrial services, software and tech-enabled services, or specialty manufacturing sectors. For more information, visit www.gemspring.com.

CONTACT: Zubin Malkani ([email protected]) or Dan Gill ([email protected])

SOURCE Gemspring Capital

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.

DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” said Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer. “We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs.”

Kevin Judice, Ph.D., CEO of DICE Therapeutics, added: “We’re eager to see our pipeline, including our oral IL-17 inhibitors, DC-806 and DC-853, benefit from Lilly’s resources and global reach and I’m excited by the prospect of watching these two talented teams in a united quest for scientific innovation. Our novel approach to discovering and advancing oral, small molecules against validated protein-protein interaction targets has even greater potential with Lilly’s industry-leading clinical development capabilities to get these medicines to patients suffering from autoimmune diseases.”

Terms of the Agreement

Lilly will commence a tender offer to acquire all outstanding shares of DICE for a purchase price of $48 per share in cash (an aggregate of approximately $2.4 billion) payable at closing. The transaction has been approved by the boards of directors of both companies.

The transaction is not subject to any financing condition and is expected to close in the third quarter of 2023, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of DICE’s common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of DICE that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer.

The purchase price payable at closing represents a premium of approximately 40% to the 30-day volume-weighted average trading price of DICE’s common stock ended on June 16, 2023, the last trading day before the announcement of the transaction. DICE’s Board of Directors unanimously recommends that DICE’s stockholders tender their shares in the tender offer.

Lilly will determine the accounting treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly’s financial results and financial guidance.

For Lilly, Kirkland & Ellis LLP is acting as legal counsel. For DICE, Centerview Partners LLC is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting the integrin α4ß7 for the treatment of inflammatory bowel disease.

About Lilly

Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. C-LLY

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding Lilly’s proposed acquisition of DICE, including regarding prospective benefits of the proposed acquisition and the DELSCAPE platform, regarding the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, regarding the Company’s product candidates and ongoing clinical and preclinical development, and regarding the accounting treatment of the potential acquisition under GAAP and its potential impact on Lilly’s financial results and financial guidance. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to consummating the proposed acquisition and any competing offers or acquisition proposals for DICE, drug research, development and commercialization, Lilly’s evaluation of the accounting treatment of the potential acquisition and its potential impact on its financial results and financial guidance, uncertainties as to how many of DICE’s stockholders will tender their stock in the tender offer, the effects of the proposed acquisition (or the announcement thereof) on DICE’s stock price, relationships with key third parties or governmental entities, transaction costs, risks that the proposed acquisition disrupts current plans and operations or adversely affects employee retention, potentially diverting management’s attention from DICE’s ongoing business operations, changes in DICE’s business during the period between announcement and closing of the proposed acquisition, and any legal proceedings that may be instituted related to the proposed acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that the proposed acquisition will be completed in the anticipated timeframe or at all, that the conditions required to complete the proposed acquisition will be met, that any event, change or other circumstance that could give rise to the termination of the definitive agreement for the proposed acquisition will not occur, that Lilly will realize the expected benefits of the proposed acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that Lilly’s financial results will be consistent with its expected 2023 guidance or that Lilly can reliably predict the impact of the proposed acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly’s and DICE’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission (the “SEC”). Except as required by law, neither Lilly nor DICE undertakes any duty to update forward-looking statements to reflect events after the date of this press release.

Additional Information about the Acquisition and Where to Find It

The tender offer for the outstanding shares of DICE described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of DICE will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and DICE will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF DICE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF DICE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of DICE at no expense to them at Lilly’s website at investor.lilly.com and (once they become available) will be mailed to the stockholders of DICE free of charge. The information contained in, or that can be accessed through, Lilly’s website is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and DICE file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly and DICE with the SEC for free on the SEC’s website at www.sec.gov.

Refer to:     

Jordan Bishop; [email protected]; 317-473-5712 (Media)

Joe Fletcher; [email protected]; 317-296-2884 (Investors)

Dan Budwick; [email protected] (DICE Media and Investors)

[Company Name] [Date]

[Headline: Your Company Name] Acquires [Acquired Company Name]

[Sub-header: Briefly state why this acquisition is significant.]

[City, Date]. [Your Company Name], [a brief description of your company], is excited to announce the acquisition of [Acquired Company Name], [a brief description of the acquired company]. This acquisition, which was officially announced [when and where the announcement was made], began [when and why the acquisition process started] and was completed on April 2024..

“[Insert quote from a high-level executive about the acquisition],” said [Name, Title].

The acquisition of [Acquired Company Name] aligns with [Your Company Name]’s strategy to [explain the purpose or strategy behind the acquisition]. Through this acquisition, [highlight the value and benefits expected from this move].

“[Insert another quote about the impact of the acquisition],” stated [Name, Title].

About [Your Company Name]

[Two to three sentences about what your company does, including major partners and mission statement].

Media Contact:

[Contact Name]

[Job Title]

[Email Address]

[Phone Number]

[Company Website]

FOR IMMEDIATE RELEASE

[Date]

[Headline: Your Company Name] Announces Strategic Acquisition of [Acquired Company Name]

[CITY, STATE] – [Your Company Name], a leader in [your industry/sector], is proud to announce the successful acquisition of [Acquired Company Name], a renowned [industry/sector] firm. This strategic move, effective as of April 2024., signifies a pivotal step in [Your Company Name]’s mission to [state your company’s strategic goals or vision].

The acquisition is set to [mention key benefits, synergies, or new opportunities]. It enables [Your Company Name] to [describe how the acquisition enhances your company’s capabilities or market reach].

“[Insert a quote expressing excitement about the acquisition],” said [Name], [Position] at [Your Company Name]. “Through this partnership, we aim to [describe potential achievements or goals post-acquisition].”

[Include an additional quote from another key figure or stakeholder regarding the acquisition].

[Your Company Name] is dedicated to a smooth integration process for [Acquired Company Name] and its workforce. Clients of [Acquired Company Name] will continue to receive the same level of exceptional service and support.

For further information, please visit [company website] or reach out to our media contact below.

About [Your Company Name]:

[Brief description of your company, its industry, and core values].

About [Acquired Company Name]:

[Brief description of the acquired company, its unique offerings, and strengths].

For Media Inquiries, Contact:

[Media Contact Name]

[Email]

[Phone Number]

[Date]

[Headline: Your Company Name] Successfully Acquires [Acquired Company Name]

[CITY, STATE] – [Your Company Name], a prominent player in [your industry/sector], is thrilled to announce the acquisition of [Acquired Company Name], a key player in [its industry/sector]. This acquisition, effective April 2024., marks a significant milestone in our journey towards [explain the strategic significance].

With this acquisition, [Your Company Name] is poised to [mention the main advantages or opportunities]. This move will enhance our ability to [explain how the acquisition benefits your company’s position or offerings].

“[Insert a thoughtful quote about the acquisition and its impact],” mentioned [Name], [Position] at [Your Company Name].

[Your Company Name] is committed to a smooth transition for the teams and customers of [Acquired Company Name]. We anticipate continued success and growth through this synergistic partnership.

Learn more about this exciting development at [company website].

About [Your Company Name]:

[Short description of your company and its mission].

About [Acquired Company Name]:

[Short description of the acquired company and its key strengths].

Media Contact:

[Contact Name]

[Position]

[Email]

[Phone Number]

Advertising & Marketing Press Release Example

Automotive Press Release Example

Banking & Financial Services Press Release Example

Books Press Release Example

Business Press Release Example

Consumer Electronics Press Release Example

Education Press Release Example

Environment & Ecology Press Release Example

Fashion Press Release Example

Fitness Press Release Example

Food & Beverage Press Release Example

Healthcare Press Release Example

Internet Technology Press Release Example

Investments Press Release Example

Personal Finance Press Release Example

Pets Press Release Example

Real Estate Press Release Example

Retailing Press Release Example

Seniors Press Release Example

Software Press Release Example

Transportation & Trucking Press Release Example

Travel Press Release Example

• Podcast Announces Major Milestone Press Release Example
• How to Write a Press Release For a Book (+Template and Examples)
• Author Announces New Book Press Release Example
• Media Network Launch Press Release Example
• Awards Announcement Press Release Example
• Foundation Publishing Press Release Example
• Cosmetics & Toy Mashup Press Release Example
• How to Write a Press Release for an Event (+Template and Examples)
• Society & Foundation Announces a Commemorative Event Press Release Example
• Individual Completes Milestone Press Release Example
• Student Wins Major Award Press Release Example
• School/University Announces Specialized Program Press Release Example
• Tech Launch of a Similar Platform Press Release Example
• Individual Announces Candidacy in Election Press Release Example
• Tech Company Announces Licensing Deal Press Release Example
• How to Write a Music Press Release (With Examples)
• Music Press Release Example
• Musician & Theater Press Release Example
• Music Producers, Directors & Songwriters Press Release Example
• Acquisition Press Release Examples [+ Templates]
• 14 Grand Opening Press Release Examples [+ Templates]
• Partnership Press Release Examples
• New Hire Press Release Examples [+ Templates]
• 14 Press Release Examples For Events [+ 3 Templates]
• Press Release Quote Examples [+ Quote Templates]
• Product Launch Press Release Examples
• Awards and Recognition Press Release Examples [+ Templates]
• Book Press Release Examples [+ Templates]
• Company Milestone Press Releases
• Product Improvement Press Release Examples [+ Templates]
• Social Cause Press Release Examples [+ Templates]
• Sports Press Release Examples
• Crisis Press Release Examples